Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.
Bally Technologies Inc. (NYSE: BYI) shares declined 1.94 percent to close at $68.85 a share Wednesday. The stock traded between $68.57 and $70.25 on volume of 259,621 shares traded. Analysts at Goldman Sachs have recently downgraded the company’s rating to “sell” from “neutral”. Shares of Bally Technologies have fallen approximately 12.0 percent year-to-date.
Find out more about Bally Technologies including full access to the free equity report at:
www.RDInvesting.com/BYI
Compugen Ltd. (NASDAQ: CGEN) shares gained 3.93 percent to close at $11.90 a share Wednesday. The stock traded between $11.52 and $12.13 on volume of 1.05 million shares traded. Analysts at Jefferies have recently initiated coverage on the company with a “buy” rating and a price target of $17.00. Shares of Compugen have gained approximately 32.0 percent year-to-date.
Find out more about Compugen including full access to the free equity report at:
www.RDInvesting.com/CGEN
Cell Therapeutics Inc. (NASDAQ: CTIC) shares declined 0.75 percent to close at $3.95 a share Wednesday. The stock traded between $3.90 and $4.08 on volume of 3.94 million shares traded. Analysts at WallachBeth have recently initiated coverage on the company with a “hold” rating and a price target of $4.50. Shares of Cell Therapeutics have gained approximately 105.0 percent year-to-date.
Find out more about Cell Therapeutics including full access to the free equity report at:
www.RDInvesting.com/CTIC
Recro Pharma Inc. (NASDAQ: REPH) shares increased 4.14 percent to close at $8.49 a share Wednesday. The stock traded between $8.23 and $8.64 on volume of 182,047 shares traded. Analysts at Brean Capital have recently initiated coverage on the company with a “buy” rating and a price target of $26.00. Shares of Recro Pharma have gained approximately 2.3 percent since its IPO.
Find out more about Recro Pharma including full access to the free equity report at:
www.RDInvesting.com/REPH
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
[email protected]